**AUB KQ1 Evidence Table (Reference ID #1190)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality****Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**Hall et al., 1987**Country:**United Kingdom**Enrollment** **period:** NR**Intervention** **setting:** Outpatient clinics**Funding:**NR**Author industry relationship disclosures:**NR**Study Design:** RCT (crossover)**Blinding:** Patients, clinicians | **Intervention:**Naproxen loading dose 550 mg followed by 275 mg every 6 hours for 5 days**Comparator:**Mefenamic acid 500 mg every 8 hours **Groups:****G1:** Naproxen in phase 1 and mefenamic acid in phase 2**G2:** Mefenamic acid in phase 1 and naproxen sodium in phase 2**Ga:** Naproxen**Gb:** Mefenamic acid**Followup:**6 cycles | **Inclusion criteria:*** Aged 18 years through menopause

Dysfunctional uterine bleedingMBL of >80ml confirmed in 2 initial control cycles**Exclusion criteria:**Pelvic inflammationUterine fibroidsLocal diseaseGross cyclic irregularitiesTaking NSAIDs, steroidsDrug sensitivityDisorder requiring medical carePoor clinic attendance**N at enrollmenta:****G1:** 19**G2:** 19**N at follow-up:** **G1:** 17**G2:** 16**Age, mean years ± SD:****G1:** 40.5 ± 3.6**G2:** 38.1 ± 4.7**BMI:**NR**Parity:**NR**Race/ethnicity:**NR**Menorrhagia duration, mean number of months ± SD:****G1:** 55.8 ± 53.0**G2:** 45.0 ± 41.4 | **Bleeding**MBL measured using the alkaline hematin method, median ml (range):**G1:** 118.5 (68, 186)**G2:** 129.3 (58, 369)**G1 vs. G2:** p=0.92Bleeding days per cycle, mean ± SD:**G1:** 8.0 ± 2.8 **G2:** 6.6 ± 1.5 Hemoglobin, mean g/dl ± SD:**G1:** 13.0 ± 1.0 **G2:** 12.1 ± 1.70**G1** **vs.** **G2:** p=0.06Serum iron, mean μmol/l ± SD:**G1:** 14.3 ± 5.96 **G2:** 11.8 ± 7.95 Tampons used, mean:**G1:** 31**G2:** 32 | **Bleeding**MBL measured using the alkaline hematin method (with slight modification to accommodate bulky material at phase 1), median ml (range):**G1:** 67.0 (15, 151)**G2:** 68.0 (22, 381)**G1 vs. BL:** p<0.001**G2 vs. BL:** p<0.001**G1** **vs. G2:** p=0.84MBL at treatment phase 2, **G1**: 64.5 (22-135)**G2**: 67.3 (18-357)**G1 vs. BL:** p<0.001**G2 vs. BL:** p<0.001**G1** **vs. G2:** p=0.69Bleeding days per cycle, mean, p value: **G1a:** 6.4**G1b:** 5.9**G2a:** 5.9**G2b:** 6.0**G1a vs. BL:** p=0.01**G1b vs. BL:** p=0.01**G2a vs. BL:** p=0.004**G2b vs. BL:** p=0.03Tampons used, mean:**G1a:** 23**G1b:** 23**G2a:** 25**G2b:** 25**G1a vs. BL:** p=0.003**G1b vs. BL:** p=0.005**G2a vs. BL:** p=0.003**G2b vs. BL:** p=0.017**Quality of life:**NR**Pain:**NR**Sexual function:**NR**Patient satisfaction:**NR**Fertility:**NR**Time to conception:**NR**Additional interventions:**NR**Adverse events, n:**Any side effects:**Ga:** 18**Gb:** 15Gastrointestinalb:**Ga:** 13**Gb:** 6Central nervous system symptomsc:**Ga:** 5**Gb:** 6Otherd:**Ga:** NR**Gb:** NR | **Overall quality:**Fair**Risk of bias:** Randomization: LowAllocation concealment:LowSelective reporting:LowBlinding patients/personnel:LowBlinding outcome assessment:LowIncomplete outcome reporting:HighOther: Low |

**Table Notes**: a 50 patients at baseline, 9 withdrew before treatment, 1 withdrew in first treatment phase, 5 had <80 cc mbl, so 35 analyzed; b Included nausea, diarrhea, abdominal discomfort and anorexia; c Complaints of light headedness, dizziness, tiredness and headache; d A small number of patients in each treatment group noted weight increase, limb pain, pelvic discomfort, and post menstrual discharge.